Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Aging with HIV: What the next major challenge is for drug development
As people with HIV live longer due to ART, new challenges are emerging. Aging with HIV is linked to higher risks of comorbidities, chronic inflammation, and drug interactions, while gaps in clinical trial inclusion and care models highlight the need for more integrated, patient-centered treatment strategies.
-
From study end to long-term insight: Choosing the right vaccine follow-up strategy
Navigating long‑term vaccine follow‑up isn’t one‑size‑fits‑all; explore the key questions that help determine the right mix of traditional studies and tokenisation.
-
From uncertainty to strategy: Guiding vaccine decisions in rare autoimmune conditions
Rare autoimmune diseases can increase patients’ vulnerability to infection and often require tailored considerations for vaccination. Read the article to learn what makes these cases distinct and what to factor in when designing a vaccine schedule.
-
Early-phase study design considerations for long-term follow-up in vaccine clinical trials
ICON experts discuss why strategic early planning is key to long-term follow-up in vaccine trials—driving stronger protocols, regulatory alignment, and meaningful outcomes.
-
Hot shots: The power and potential of study tokenisation for vaccine research and post-commercialisation
Discover how clinical trial tokenisation helps sponsors gain patient insights and enable long-term data collection—without adding burden to patients or sites.
-
Overcoming challenges with maternal vaccine trials
In this article from pharmaphorum, Dinah Knotts, VP of Project Management in Vaccines and Infectious Diseases and Mitsu Rana, Senior Director of Project Management outline some of the challenges with maternal vaccine trials and how with careful planning and execution by researchers, these can be overcome throughout the trial process.
-
From Vaccines to Oncology and Beyond: Tracking mRNA’s Progress
In this article, ICON’s Andreas Dreps and Martin Lachs discuss how the success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
-
Decoding pandemic precision: From SARS-CoV-2 to influenza vaccination strategies
The need for public health officials to be able to model the spread of infectious diseases has never been more apparent than in the early days of the SARS-CoV-2 pandemic, but what needs to change? Read the article by ICON epidemiologist Dr. Richard Pitman in Open Access Government.
-
Logistical considerations in mRNA vaccine development
In this article, ICON’s Andreas Dreps and Martin Lachs discuss the logistical considerations in mRNA vaccine development.
©BioPharm International
-
ICON partners with US Government for clinical trials of Covid-19 vaccines
The article on Clinical Trials Arena reports that ICON will conduct a phase 2b clinical trial for the US BARDA-selected Covid-19 vaccine candidate as part of Project NextGen.
